NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3
TG Therapeutics Announces Schedule Of Data Presentations For BRIUMVI® (Ublituximab) In Multiple Sclerosis At The Americas Committee For Treatment And menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
20.02.2024 - NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) - TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating . Seite 1